The partnership says it formed to provide the smaller sized companies with access to advanced technologies, operational experience, and regulatory knowledge to implement more patient-focused trials and to help businesses realize the efficiencies of the DCT approach.
Mark Goldberg, chairman and chief executive officer of Allucent, said, "This will enable a highly customized, decentralized clinical trial offering that's laser-focused on meeting the current needs of small and emerging biotech companies.
“With this launch, we're helping our clients harness new insights and technologies to be more patient-centric and realize the potential and efficiencies of decentralized approaches to clinical research."
The announcement coincided with the 2023 World Orphan Drug Congress, where Allucent led a panel session on the value of decentralized study designs and protocol optimization, especially for rare disease therapeutic development.
Post-COVID-19, Allucent said it embraced new digital technologies and enhanced its patient-centric approaches and guidance for optimizing clinical protocols. The Allucent Patient Direct Trials partnership says it will use this experience to address the needs of many small and emerging biotech companies that may not have the in-house resources required to design and oversee DCTs.
Working with Thread, Allucent's team of regulatory and product development consultants say they can guide sponsors in determining the most effective and efficient digital strategies for remote engagement and data collection for their studies.
Many pharmaceutical and research organizations around the world have increasingly adopted DCTs to make patient participation more accessible and manageable. The technology can make sure DCTs can expedite recruiting, help retain participants, and increase the diversity of the overall participant pool so trial results are more representative of real-world effectiveness.
